Financial Performance Expectations - The company expects a net profit attributable to shareholders to rise by 0% to 20% compared to the same period last year, with an estimated profit range of 95.87 million to 115.05 million yuan[2]. - The overall performance is expected to increase compared to the same period last year due to the offsetting effects of the changes in product sales structure[4]. - Non-recurring gains and losses are expected to have a minimal impact on the company's performance[5]. Product Development and Sales - The company launched a new self-developed product, the AC-Hib combination vaccine, which contributed to an increase in sales revenue from self-developed products year-on-year[4]. - Sales revenue from agency products decreased year-on-year, impacting the overall sales structure[4].
智飞生物(300122) - 2015 Q2 - 季度业绩预告